L1TD1 - a prognostic marker for colon cancer

Abstract

Background Prognostic markers specific to a particular cancer type can assist in the evaluation of survival probability of patients and help clinicians to assess the available treatment modalities. Methods Gene expression data was analyzed from three independent colon cancer microarray gene expression data sets ( N = 1052). Survival analysis was performed for the three data sets, stratified by the expression level of the LINE-1 type transposase domain containing 1 ( L1TD1 ). Correlation analysis was performed to investigate the role of the interactome of L1TD1 in colon cancer patients. Results We found L1TD1 as a novel positive prognostic marker for colon cancer. Increased expression of L1TD1 associated with longer disease-free survival in all the three data sets. Our results were in contrast to a previous study on medulloblastoma, where high expression of L1TD1 was linked with poor prognosis. Notably, in medulloblastoma L1TD1 was co-expressed with its interaction partners, whereas our analysis revealed lack of co-expression of L1TD1 with its interaction partners in colon cancer. Conclusions Our results identify increased expression of L1TD1 as a prognostic marker predicting longer disease-free survival in colon cancer patients. Electronic supplementary material The online version of this article (10.1186/s12885-019-5952-2) contains supplementary material, which is available to authorized users.

ETV4 plays a role on the primary events during the adenoma-adenocarcinoma progression in colorectal cancer

“…These distinctive roles are dependent on its interaction partners. Several co-expression partners of L1TD1 already described in CRC have also been observed in our study, such as SPINK4, RETNLB, CLCA1, FcGBP, HEPACAM2, ITLN1 and , DEFA5 [ 42 ]. The common genes observed in our study with previous meta-analysis and other studies reinforces the importance of our findings.…”

Identification and Validation of New Cancer Stem Cell-Related Genes and Their Regulatory microRNAs in Colorectal Cancerogenesis

“…In human embryonal stem cells, L1TD1 has also been associated with canonical markers of pluripotency that are also involved in cancerogenesis, such as OCT4 , NANOG , LIN28 and SOX2 [ 15 ]. With the use of bioinformatics analysis, a higher expression of L1TD1 in CRC was shown to be associated with longer disease-free survival [ 16 ]. Our results showed a positive trend of expression of L1TD1 to CRC cancerogenesis.…”

“…Moreover, in bladder cancer, it was suggested as a promising target for conjugate therapy [ 19 ]. A bioinformatics study on CRC showed differentially expressed SLITRK6 together with L1TD1 and ST6GALNAC1 [ 16 ], and it was downregulated in CRC compared to adenomas using microarray expression analysis [ 41 ]. However, our results showed no significant differences in expression between adenomas and CRC.…”

“…STn antigen has been used as a target in immunotherapy trials for breast, colon and ovarian cancer [ 23 ]. Data regarding its expression and function in normal human tissues are limited [ 16 , 23 ]. It has also been associated with stem cell maintenance in ovarian cancer [ 42 ], as well as with the maintenance of isolated stem cells of CRC [ 23 ].…”

“…L1TD1, a gene-encoding RNA-binding protein, has been identified as a marker for human embryonic stem cells, their renewal and cancer cell proliferation. It has been associated with RNA transcription, splicing, processing, localization, stability and translation [ 13 , 14 , 15 , 16 ]. SLITRK6 , an integral membrane protein, has been found to be highly expressed in human adult neural stem-like cells and in several cancers.…”